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Monoclonal antibodyRegulatory T (Treg) cells are activated and suppress immune responses during infection, and are
characterized as CD4+CD25hiFOXP3+. Ex vivo studies demonstrate that Treg cells potentially suppress
anti-HIV-1 T cell responses. Lentivirus-induced CD4+CD25hi Treg cells were ﬁrst described in feline
immunodeﬁciency virus (FIV)-infected cats. In the present study we demonstrate that anti-feline CD25
monoclonal antibody (mAb) therapy depletes Treg cells in FIV-infected cats for 4 weeks and does not
exacerbate viral replication or proinﬂammatory cytokine production. Signiﬁcant FIV-speciﬁc immune
responses are revealed in Treg cell-depleted cats. These anti-FIV effector cells exist prior to Treg cell
depletion and are not expanded while Treg cells are depleted. Importantly, cats receiving the Treg cell-
depleting mAb are able to produce a robust humoral response to new antigen. We propose that short-term in
vivo Treg cell depletion during chronic HIV-1 infection could provide a window of opportunity for
therapeutic vaccination in individuals with controlled viral replication..R. Mikkelsen),
biosciences.com (E.A. Egan),
Road, Suite 240, PO Box 14827,
ampusDrive, Suite 405, Raleigh,
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
In the face of prolonged exposure to antigen, many regulatory
mechanisms are in place to restrict potential damage to the host
posed by chronically activated immune responses. Regulatory T
(Treg) cells are important negative regulators of activated T cells,
are activated in the periphery during immune responses to pathogens,
and are phenotypically characterized as CD4+CD25+FOXP3+ (Fonte-
not et al., 2005; Kinter et al., 2004; Rouse et al., 2006; Weiss et al.,
2004). Lentivirus-induced CD4+CD25+ Treg cells were ﬁrst described
and functionally characterized in FIV-infected cats (Joshi et al., 2004;
Vahlenkamp et al., 2004). Like HIV-1, FIV is a lentivirus that causes a
chronic progressive disease resulting in AIDS (Bendinelli et al., 1995;
Dunham, 2006; VandeWoude and Apetrei, 2006).
Ex vivo studies clearly demonstrate that Treg cells have the
potential to suppress anti-HIV-1 T cell responses (Aandahl et al., 2004;
Kinter et al., 2007; Kinter et al., 2004; Legrand et al., 2006;Weiss et al.,
2004). Correlative epidemiologic studies present conﬂicting picturesof the potential role of Treg cells in vivo (Boasso et al., 2006; Chougnet
and Shearer, 2007; Sempere et al., 2007). On one hand, the
localization of suppressive Treg cells to the lymph nodes of HIV-1-
infected patients may prevent potentially beneﬁcial HIV-1-speciﬁc
cytotoxic T lymphocyte (CTL) activity inmajor sites of viral replication
(Kinter et al., 2007). Treg cells have been shown to redistribute to
lymphoid tissue during HIV-1 infection where they are positioned to
modulate cell-mediated immunity (Andersson et al., 2005; Nilsson
et al., 2006). On the other hand, several investigators have proposed
that HIV-1-speciﬁc immune activation in the absence of Treg cells
could lead to increased viral replication and activation-induced cell
death, causing the characteristic decline of CD4+ T helper cells
observed in HIV-1 infected individuals over time (Aandahl et al.,
2004; Eggena et al., 2005; Kinter et al., 2004). Lymph node ﬁbrosis,
thymic dysfunction, clonal exhaustion, and loss of memory T cell pools
due to lasting immune activation have adverse effects on host health
and quality of antiviral immune responses (Appay and Sauce, 2008).
Treg cells, as key modulators of immune activity, are in a unique
position to either subdue harmful chronic hyperactivation during
lentiviral infection or prevent a potentially beneﬁcial antiviral
response. From observations made thus far, no clear resolution has
been reached concerning the undoubtedly complex role of Treg cells
in the face of lentiviral infection. Direct in vivo modulation of Treg
cells in a relevant animal model is necessary to help elucidate the
speciﬁc function of Treg cells and their effect on host health during
lentiviral infection.
Naturally occurring, thymically derived Treg cells and adaptive
Treg cells have been phenotyped using a variety of molecules in
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surface marker. Intranuclear expression of the forkhead box P3
(FOXP3) transcription factor is associated with Treg cell function
within and outside of the CD4+CD25+ cell population, but labeling of
FOXP3+ cells for phenotypic identiﬁcation renders them unusable in
live-cell assays (Fontenot et al., 2005). Although CD25, as well as
FOXP3, is upregulated upon T cell activation and is thus not an
exclusive Treg cell marker, only the CD4+CD25+ cell population has
been consistently described as functionally immunosuppressive
across species, and detection of CD4 and CD25 expression remains
the best live-cell identiﬁer of Treg cells (Gavin et al., 2006; Morgan
et al., 2005; Roncador et al., 2005).
Monoclonal antibody (mAb) depletion of cells in vivo is a useful
method to determine the signiﬁcance of a particular cell population in
immune processes. Depletion of Treg cells using anti-CD25 antibody
has been used therapeutically and to investigate the role of Treg cells
in disease pathogenesis. For example, CD25+ cell depletion with mAb
therapy in combination with a melanoma vaccine or a human
papilloma virus vaccine in mouse models results in a greater
antigen-speciﬁc immune response (Chuang et al., 2009; Goforth
et al., 2009). The therapeutic agent, denileukin diftitox, has repeatedly
been shown to be effective in treating cutaneous T cell lymphomas as
well as other lymphoid malignancies by removing suppressive CD25+
Treg cells, thus allowing the patient to mount a productive anti-tumor
response (Wong et al., 2007).We have developed amethod to deplete
Treg cells from the cat using an anti-feline CD25 mAb (Smithberg
et al., 2008). Here, we report that Treg cell depletion can unmask an
existing cell-mediated anti-FIV response in vivo. Although there was
concern that Treg cell depletion could lead to non-speciﬁc immune
activation, proinﬂammatory cytokine production, or increased viral
burden, in animals with low viral set-point no such side effects were
observed. Finally, the introduction of a novel antigen induced much
more robust humoral responses in FIV-infected cats depleted of Treg
cells as compared to Treg cell-sufﬁcient FIV-infected cats or FIV-naïve
cats depleted of Treg cells in previous studies.
Results
Anti-CD25 monoclonal antibody treatment depletes Treg cells in
FIV-infected cats without disturbing the immune cell proﬁle
We sought to verify whether Treg cells could be depleted in FIV-
infected cats with the same kinetics we previously observed in FIV-
naïve cats (Smithberg et al., 2008). Eighteen cats that had been
infected with FIV for 14 months were randomly divided into three
groups of six cats each and injected intraperitoneally with either
anti-CD25mAb, isotype control mAb (IgG2a, κ light chain), or vehicle
control (saline). The nadir of CD4+CD25+ cell depletion occurred at
day 10 after anti-CD25 mAb treatment, similar to our previous
observations in FIV-naïve cats (Smithberg et al., 2008). Depletionwas
most dramatic in the CD4+CD25hi-expressing T cell population (Figs.
1A, C). Treg cells express CD25 at higher densities than effector cells,
therefore, CD4+CD25hi T cells represent a more pure population of
Treg cells (Baecher-Allan et al., 2004; Smithberg et al., 2008). An 89%
average reduction in the absolute number of circulating CD4+CD25hi
cells compared to day 0 levels was observed in 5 out of 6 cats that
received anti-CD25 mAb (Fig. 1A). FOXP3 is an intranuclear
transcription factor associated with the suppressive phenotype of
CD4+CD25+ Treg cells inmice, humans, and cats (Bettelli et al., 2005;
Fontenot et al., 2003; Lankford et al., 2007; Zheng et al., 2007). A 78%
reduction in the absolute number of circulating CD4+CD25+FOXP3+
cells compared to day 0 levels was observed in 5 out of 6 cats that
received anti-CD25 mAb (Fig. 1A). No depletion was observed in one
cat treated with anti-CD25 mAb even though antibody was detected
on the surface of target cells and the cat mounted an anti-mouse IgG
antibody response. The reason for the failed depletion is not certainbut we cannot rule out the possibility that part of the antibody dose
may have been delivered into the intestine or bladder where it would
be ineffective. The data for this cat was excluded from subsequent
analysis.
Circulating CD4+CD25hi cells rebounded by day 29 after anti-
CD25mAb treatment; however, we have previously shown that anti-
CD25 mAb treatment reduces FOXP3 mRNA levels in blood and
tissues up to day 35 post-treatment, suggesting that rebound
circulating CD4+CD25hi T cells at day 29 are activated CD4+CD25+
effector cells rather than Treg cells (Smithberg et al., 2008). To verify
the depletion of CD4+CD25hi Treg cells from lymphoid tissues, a
second study including eight FIV+ cats divided into two groups of
four was performed. The cats were treated with either anti-CD25
mAb or isotype control mAb. At day 23 post-treatment the
percentage of CD4+CD25hi Treg cells in the lymphoid tissues of the
CD25-depleted cats was on average 84% lower than control-treated
cats (Fig. 1B). Likewise, the percentage of CD4+CD25+FOXP3+ Treg
cells in the lymphoid tissues of the CD25-depleted cats was on
average 68% lower than control-treated cats (Fig. 1B).
Other lymphocyte subsets were not signiﬁcantly affected by anti-
CD25 mAb, isotype control mAb, or saline treatment (data not shown).
Anti-CD25 mAb administration effectively depleted CD4+CD25hi Treg
cells in FIV+ cats with kinetics similar to FIV-naïve cats without causing
signiﬁcant alterations in other lymphocyte subpopulations, includingno
signiﬁcant impact on CD8+ T cell, B cell, monocyte, granulocyte, or total
lymphocyte numbers (data not shown).
FOXP3 expression is upregulated in CD4+CD25+ cells of cats receiving
isotype control antibody, but not anti-CD25 antibody
In chronically-infected FIV+ cats receiving isotype control mouse
antibody, intranuclear FOXP3 expression was signiﬁcantly upregu-
lated in the PBMC CD4+CD25+ Treg cell population at day 10 post-
treatment, while cats receiving anti-CD25 antibody or receiving no
antibody had decreased or unchanged FOXP3 expression in the Treg
cell population, respectively (Fig. 1D). Human Treg cells have been
shown to upregulate FOXP3 expression upon TCR stimulation ex vivo
(Allan et al., 2007; Tran et al., 2007). It is probable that the
upregulation observed in the isotype control antibody treated cats
was due to transient FOXP3 expression related to Treg cell activation
in response to the mouse antibody which was recognized as a foreign
antigen (Gavin et al., 2006; Morgan et al., 2005). The data suggest that
depletion of CD4+CD25+ Treg cells with the anti-CD25 antibody
eliminated the cell population responsible for FOXP3 upregulation in
response to the mouse antigen.
Viral burden is unaffected by anti-CD25 mAb treatment
Viral RNA in plasma and integrated proviral DNA in cells are
established indicators of virologic status, however, FIV-NCSU1-
infected cats in the chronic stage of disease exhibit low levels of
viral burden compared to the acute phase (Stevens et al., 2004). It has
been proposed that in HIV-1 and pathogenic SIV infection, persistent
viral replication and associated T cell proliferation result in abnormal
lymphoid architecture, diminished immune function and the devel-
opment of AIDS (Brenchley et al., 2006; Grossman et al., 2006).
Therefore, prolonged immune activation as a consequence of
transient Treg cell depletion would be undesirable. Indeed, CTLA-4
blockade lasting over 9 weeks during acute SIVmac251 infection of
macaques results in elevated viral replication (Cecchinato et al.,
2008).
We asked whether Treg cell depletion over a period of 4 weeks
would lead to increased viral replication due to immune hyperactiva-
tion or lead to a reduction of infected cells and reduced viremia and
provirus. Plasma viremia did not change signiﬁcantly on days 10, 21 or
23, 29, 42, or 60 post-treatment as compared to baseline levels (not
Fig. 1. Depletion of Treg cells by anti-CD25mAb treatment. Groups of six cats each received 9 mg/kg anti-CD25mAb (9F23) or 9 mg/kg isotype control mAb (CRL-1689, (IgG2a, κ
light chain)) i.p. on day 0. A third group of cats received 3 ml/kg saline on day 0. Lymphocytes were labeled to detect surface CD4 and CD25 and intranuclear FOXP3 by ﬂow
cytometry. (A) Percent CD4+CD25hi and CD4+CD25+FOXP3+ PBMCs within gated lymphocytes was determined on days 0, 10, 21, 29, 42, and 60 following treatment and
multiplied by the absolute number of peripheral blood lymphocytes. Absolute CD4+CD25hi cell numbers are reported relative to day 0 absolute numbers, which have been
normalized to 100. Absolute CD4+CD25+FOXP3+ cell numbers are reported. Statistical signiﬁcance was calculated compared to day 0 values. Means±SEM are shown. (B) In a
second study two groups of four cats each were treated with 9 mg/kg anti-CD25 mAb or 9 mg/kg isotype control mAb i.p. on day 0. Lymphoid tissues were harvested on day 0 or
day 23. CD4+CD25hi and CD4+CD25+FOXP3+ cell percentages within gated lymphocytes were determined by ﬂow cytometry for the indicated tissues. Means±SD are shown.
Statistical signiﬁcance was calculated compared to isotype control group for each tissue. * indicates pb0.05. (C) A representative dot plot of PBMCs isolated on day 0 and day 10 of
one cat receiving anti-CD25 mAb treatment is shown. The numbers in gate P1 represent percentage CD4+CD25hi cells within gated lymphocytes. The numbers in quadrant Q2-2
represent CD4+CD25+ cells within gated lymphocytes. (D) Percent FOXP3+ cells within gated CD4+CD25+ PBMCs is reported for days 0, 10, 21, 29, 42, and 60 post-treatment.
Statistical signiﬁcance was determined compared to day 0 values. * indicates pb0.05.
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treatment groups. Likewise, no signiﬁcant changes in provirus were
observed in PBMC and tissues between treatment groups (Fig. 2A; not
detectable to 40,000 proviral copies/106 cells). In addition, we asked
whether changes in provirus levels could be detected in isolated
lymphocyte subsets. Peripheral LNs harvested on day 0 and on day 23
post-treatment were sorted for CD4+CD25−, CD4+CD25hi, CD8+, and
CD21+ lymphocytes. No signiﬁcant changes in proviral load were
noted between day 0 and day 23 in these lymphocyte subsets from
either the CD25 depleted group or isotype control group or between
groups at either time point (Fig. 2B). Overall, we observed no
systemic reduction or increase in provirus or plasma viremia due toTreg cell depletion. From these data we conclude that it is unlikely
that short-term Treg cell depletion in individuals with low viral
burden would result in increased immune hyperactivation or
increased viral set-point.
It has been proposed that Treg cells may be preferentially infected
during the acute phase of lentiviral infection and that Treg cells may
serve as a reservoir of latent or replicating virus (Antons et al., 2008;
Joshi et al., 2005b; Joshi et al., 2004; Mexas et al., 2008; Oswald-Richter
et al., 2004; Tran et al., 2008). We examinedwhether CD4+CD25hi Treg
cells, the target of depletion in this study, host more integrated
provirus than other lymphocyte subsets during the chronic stage of
FIV infection. If CD4+CD25hi cells are a productive viral reservoir, it is
Fig. 2. Viral burden is unaffected by anti-CD25mAb treatment. To detect provirus in PBMCs and tissue samples, quantitative real-time PCRwas performed on extracted DNA samples.
FIV DNA copy number was quantiﬁed relative to CCR5 copy number. (A) Provirus was detected in mesenteric lymph node and spleen at day 60 post-treatment. (B) Single cell
suspensions of popliteal lymph nodes (n=4/group) harvested before treatment and prescapular lymph nodes (n=4/group) harvested 23 days after mAb treatment were sorted on
a MoFlo cell sorter (Dako) for CD4+CD25−, CD4+CD25hi, CD8+, and CD21+ lymphocytes. Isolated populations were at least 95% pure. Provirus was quantiﬁed per 106 cells for each
lymphocyte subset. The last two bars in each graph represent the sum of proviral copies per 106 cells in the four lymphocyte subsets. (D) Provirus was detected in lymphocyte
subsets from popliteal lymph nodes harvested before treatment (n=8). Means±SD are shown.
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has previously been shown that B cells are the major lymphocyte
reservoir during the asymptomatic stage of FIV, but we questioned
whether CD4+CD25hi Treg cells were infected to a greater extent as
compared to CD4+CD25− conventional T cells (Dean et al., 1996). As
shown in Fig. 2C, Treg cells did not carry more integrated FIV provirus
than CD4+CD25− T cells, suggesting that the Treg cells depleted in
this study were not a preferential reservoir of provirus during the
chronic phase of disease.
Immunologic responses against FIV are transiently improved after
anti-CD25 mAb treatment
To assess anti-FIV T cell responses in cats depleted of Treg cells,
lymphoid tissue single cell suspensions were evaluated by ELISPOT for
IFN-γ production in response to FIV p24 and Env peptide pools. IFN-γ
responses against FIV peptides were signiﬁcantly greater in lymph
node lymphocytes 29 days after cats received anti-CD25 mAb ascompared to control groups. However, this improvement in the anti-
FIV response did not persist to day 60 (Fig. 3A).
We then asked if the increase in FIV-speciﬁc IFN-γ secretion in the
CD25 depleted group was due to in vivo expansion of anti-FIV effector
cells during Treg depletion or if the activity of these cells was simply
unmasked by Treg cell depletion. An IFN-γ ELISPOT assay was
performed in which CD4+CD25− and CD8+ T cells were puriﬁed
and segregated from Treg cells and cultured with Env peptides both
before and 23 days after mAb treatment. We reasoned that if antiviral
effector cell frequency increased in the absence of Treg cell inﬂuence,
the number of IFN-γ secreting cells would be greater in the ELISPOT
cultures on day 23 than on day 0 in the CD25 depleted group. If the
effector cells were preexisting and not expanded after Treg cell
depletion, then approximately the same number of IFN-γ secreting
cells would be observed on day 0 and day 23. Indeed, we found that
the IFN-γ-producing FIV-speciﬁc T cells were present in vivo before
Treg cell depletion and were not expanded during Treg cell depletion
(Fig. 3B).
Fig. 3. FIV-speciﬁc IFN-γ responses are transiently improved after anti-CD25 mAb treatment. (A) Popliteal lymph node cells, medial iliac lymph node cells, and lamina propria
lymphocytes were incubated for 36 h with 100 µg/ml FIV Env or FIV p24 peptide pools. IFN-γ spot forming cells (SFCs) per million cells from CD25 depleted, isotype control, and
vehicle control-treated groups were determined by ELISpot. (B) CD4+CD25− and CD8+ T cells from popliteal lymph nodes on day 0 and prescapular lymph nodes on day 23 were
cultured with Env peptides in the absence of Treg cells. IFN-γ SFCs were determined by ELISPOT. ■ indicates isotype control group; ▼, CD25 depleted group. * indicates pb0.05.
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or TNF-α production
In multiple experimental models involving cutaneous, pulmo-
nary, or intestinal inﬂammation, Treg cells have been shown to
possess anti-inﬂammatory capabilities (Read et al., 2000; Sather
et al., 2007). HIV-1 disease progression to AIDS correlates highly with
immune activation and inﬂammation (Appay and Sauce, 2008;
Grossman et al., 2006). Therefore, the possibility that Treg cell
depletion in animals with ongoing chronic lentiviral infection could
induce proinﬂammatory T cell cytokineswas addressed in ourmodel.
We analyzed CD4+ and CD8+ T cells for intracellular IL-2 and TNF-α
by ﬂow cytometry before and 23 days after mAb treatment in
peripheral lymph nodes. No signiﬁcant increase in IL-2 or TNF-α
cytokine production in either the CD25 depleted or control groupwas
observed over baseline levels after treatment (Figs. 4A, B). Transient
Treg cell depletion in chronically FIV-infected cats does not result in
increased T cell IL-2 or TNF-α production.
FIV-infected cats treated with anti-CD25 mAb produce a more robust
humoral response to a primary immune stimulus
Treatment of cats with mouse mAb induces an anti-mouse IgG
response that ultimately restricts the duration of activity of adepleting antibody such as anti-CD25 mAb, and we have previously
reported the kinetics of this response (Smithberg et al., 2008). The
mouse antibody also acts as a novel antigen that can be used to assess
the primary immune response under Treg cell-depleted conditions.
The development of the anti-mouse IgG response in this and previous
studies was monitored using a quantitative ELISA. We found FIV-
naïve cats treated with either anti-CD25 mAb or isotype control mAb
produced similar anti-mouse IgG titers, indicating that the antige-
nicity between the twomAbs is similar and that Treg cell depletion in
speciﬁc-pathogen-free cats did not improve the primary immune
response (Supplemental Fig. 2).
Surprisingly, in the present study FIV-infected cats depleted of
Treg cells produced anti-mouse IgG titers signiﬁcantly higher than
cats receiving isotype control antibody. This was true whether the
serum titers were measured against the anti-CD25 mAb (Fig. 5A) or
the isotype control mAb (Fig. 5B). Since anti-mouse IgG levels in
Treg cell-depleted, chronically FIV-infected cats were at levels
similar to those previously observed in FIV-naïve cats, it is most
likely that the presence of activated Treg cells in isotype control-
treated, FIV-infected cats resulted in an attenuated response
against mouse immunoglobulin. Thus, these data suggest Treg cell
depletion allows the induction of a more robust primary humoral
immune response than would otherwise be possible during chronic
lentiviral infection. Serum IgG titers against FIV p24 or FIV Env
Fig. 4. Anti-CD25 treatment does not result in elevated constitutive T cell IL-2 or TNF-α
production. Intracellular IL-2 and TNF-α staining was performed on lymphocytes after a
6 hour incubation with 1× monensin, surface phenotype staining, and ﬁxation with 2%
paraformaldehyde. The cells were permeabilized with BD Perm/Wash buffer. (A) IL-2+
and (B) TNF-α+ cells per million CD4+ or CD8+ T cells were quantiﬁed by ﬂow
cytometry in popliteal lymph nodes before mAb treatment and prescapular lymph
nodes 23 days after mAb treatment. ■ indicates isotype control group; ▼, CD25
depleted group.
Fig. 5. Cats treated with anti-CD25 mAb produce a more robust humoral response
against mouse immunoglobulin. Serum was harvested on days 0, 10, 21, 29, 42, and
60 after treatment from cats treated with either anti-CD25 mAb or isotype control
mAb. ELISA plates were coatedwith either (A)mouse anti-feline CD25 clone 9F23 or
(B) isotype control mouse anti-YFA clone CRL-1689 and then incubated with 2-fold
serial dilutions of serum samples. Anti-mouse serum IgG was subsequently
detected. Positive antibody titers were calculated based on a 3-fold higher optical
density than negative controls. Means±SEM are shown. Statistical signiﬁcance was
determined between groups for each time point. * indicates pb0.05.
168 S.R. Mikkelsen et al. / Virology 403 (2010) 163–172remained unchanged throughout the course of the study (data not
shown).
Discussion
The role of Treg cells in the pathogenesis of HIV-1 is a topic of great
interest. From existing data it is difﬁcult to predict whether Treg cells
play a beneﬁcial or a detrimental role during lentivirus infection,
depending on the experimental model used, stage of disease, and the
anatomical source of Treg cells. On one hand several studies have
shown that CD4+ and CD8+ T cell responses are improved after the ex
vivo removal of Treg cells from cultures (Aandahl et al., 2004; Baker
et al., 2007; Kinter et al., 2007; Weiss et al., 2004). On the other hand,
studies that show a positive correlation between Treg cell frequency
and disease non-progression argue that Treg suppression of inﬂam-
matory responses reduces the spread and replication of virus
(Andersson et al., 2005; Apoil et al., 2005; Kinter et al., 2004;
Oswald-Richter et al., 2004). Indeed, it is not clear whether Treg cell
frequency is increased or decreased during chronic HIV-1 infection
(Apoil et al., 2005; Kinter et al., 2004; Tsunemi et al., 2005; Weiss
et al., 2004). In vivo manipulation of Treg cells using a relevant animal
model can help ﬁll the knowledge gaps left by ex vivo and in vitro
studies regarding the nature of Treg cells in HIV-1 disease anddetermine the feasibility of therapeutic strategies to modulate Treg
cell function.
In the present study we employed the well-characterized FIV/cat
model to investigate the in vivo signiﬁcance of Treg cell activity
during the asymptomatic phase of lentivirus infection. Treg cell
depletion results in an improved antiviral T cell response during the
period of depletion, but the increased antiviral response did not
persist after a rebound of Treg cells in lymphoid tissues. This
demonstrates that CD4+CD25+ Treg cells suppress FIV-speciﬁc
immune responses in vivo. However, we could not detect an
expansion of FIV-speciﬁc effector cells during the transient period
of Treg cell depletion. This result is not surprising given that the
chronically FIV-infected cats in this study had very low viremia.
Without adequate viral antigenemia there is no reason to expect an
expansion of cell-mediated response. This conclusion is supported by
the observation that anti-FIV antibody responses did not increase in
Treg cell-depleted animals. This is similar to what might be expected
if Treg cell depletion is attempted in HIV-1 patients that are
controlling viral replication or are receiving anti-retroviral therapy.
Thus, if Treg cell depletion is to be considered as part of an attempt to
improve immune responses in HIV-1 infected people, it would most
likely be necessary to add a therapeutic vaccine to the strategy. A
window of Treg cell depletion may provide an opportunity to boost
antiviral T and B cell responses. In this regard the present study offers
encouraging results.
The use of a mouse monoclonal antibody to deplete Treg cells in
cats limits the number of times a cat can be treated before a robust
anti-mouse antibody response is generated. However, this foreign
169S.R. Mikkelsen et al. / Virology 403 (2010) 163–172protein provided the opportunity to assess a novel immune response
in Treg cell-depleted and control antibody treated animals. A subset of
CD4+CD25+CD69− Treg cells has been shown to be capable of
suppressing B cell class switching and antibody production by
interfering with T cell help in germinal centers of lymph nodes or
by interacting directly with B cells in germinal centers (Lim et al.,
2005; Lim et al., 2004). It has previously been shown that cats
chronically infected with FIV and exposed to either a variety of
infectious agents or antigens develop delayed and blunted humoral
immune responses as compared to FIV-naïve cats (Reubel et al., 1994;
Reubel et al., 1992). However, the robust anti-mouse mAb humoral
response in Treg cell-depleted animals demonstrates the potent
suppressive inﬂuence Treg cells can have on the humoral arm of the
immune system and the capacity of the immune system to respond
even during a state of CD4 depletion and immune dysfunction.
Presumably, this could be extended to cell-mediated responses but
this was not directly evaluated in this study. Perhaps equally
important is that Treg cells from FIV+ cats that receive a non-
depleting isotype control mAb rapidly upregulate FOXP3 protein. In
FIV-naïve cats from a previous study, no such Treg cell induction was
observed when cats were identically treated with the isotype control
mAb (Smithberg et al., 2008). Treg cells increase FOXP3 expression
during acute FIV and SIV infection, indicating an increase in
suppressive function of these cells (Estes et al., 2006; Kornfeld et al.,
2005; Mexas et al., 2008). It has also been reported that FIV infection
leads to increased Treg cell activation (Mexas et al., 2008; Vahlen-
kamp et al., 2004). Our data support the notion that FIV infection
results in elevated Treg cell activity under steady-state conditions that
may prime for heightened suppressive Treg cell responses to novel
antigens and contribute to impaired immune responses. The dramatic
difference in antibody response to a novel antigen between groups
receiving Treg cell-depleting mAb versus isotype control mAb is likely
a combination of removing Treg cell suppression on one hand and
excessive Treg cell induction on the other hand.
There is concern that Treg cell depletion, whether in the course of
HIV-1 disease pathogenesis or via treatment strategies, could
exacerbate the vicious cycle of immune activation, viral replication
and CD4+ T cell depletion. Whether this scenario could play out likely
depends on the viral set-point, the immune set-point, the duration
and extent of Treg cell depletion, and the degree to which Treg cells
represent a viral reservoir. This study suggests that a low viral set-
point will not be altered if the immune system is functional in the
absence of Treg cells. Again, if Treg cell depletion were to be
attempted in humans with HIV-1, as part of the patient selection
process it would be prudent to demonstrate that an increased CTL
response is possible with Treg cell depletion in vitro. From the present
study we can conclude that under the conditions of low viral set-point
and a functional cell-mediated immune response, Treg cell depletion
via anti-CD25 mAb treatment is unlikely to lead to increased plasma
viremia or induce T cell IL-2 or TNF-α. In support of this conclusion,
Hryniewicz et al. treated chronically SIVmac251-infected macaques
with a CTLA-4-blocking mAb in order to interfere with one
mechanism of Treg cell suppression in vivo. The study showed that
CTLA-4 blockade did not increase viremia after cessation of ART
treatment and even decreased provirus in lymph nodes as compared
to control-treated animals (Hryniewicz et al., 2006). While high
percentages of FOXP3+ PBMCs have been associated with decreased T
cell activation, increased CD4+ cell numbers, and decreased HIV-1
provirus, a short duration of Treg cell depletion did not cause
problematic immune activation leading to viral replication, even
though the mAb treatment induced a measurable immune response
(Chase et al., 2008; Ndhlovu et al., 2008). In addition, transient Treg-
depleting therapy is used in for a variety of conditions in humans and
no generalized inﬂammation has been described. This is most likely
due to the incomplete depletion of CD25hi Treg cells, lack of depletion
of other regulatory cells, the transient nature of the depletions, andthe probable lack of a role for Treg cells in inﬂammatory processes
such as sepsis (Hein et al.,; Rech and Vonderheide, 2009). In addition,
mutation of FOXP3 leading to a complete lack of Treg cells in scurfy
mice and IPEX in humans is not associated with generalized
inﬂammation (Wildin et al., 2002; Ziegler, 2006). These diseases are
lymphoproliferative with inﬂammation in isolated tissues being
highly variable or absent. Whether administration of a therapeutic
vaccine during Treg depletion in chronically-infected animals would
be able to reduce viral set-point or would instead be confounded by
activation-induced viral replication remains to be determined.
CD4+CD25+FOXP3+ Treg cells have been shown to express CXCR4
or CCR5 and be particularly susceptible to lentiviral infection as
compared to conventional T cells both in vitro and in vivo (Antons
et al., 2008; Joshi et al., 2005b; Mexas et al., 2008; Oswald-Richter
et al., 2004; Tran et al., 2008). Because Treg cells have been shown to
produce more FIV viral particles than conventional T cells when
activated with mitogen or IL-2 in vitro, they are proposed to be a
potential viral reservoir (Joshi et al., 2005a; Joshi et al., 2004). We
show that CD4+CD25hi T cells do not carrymore provirus as compared
to CD4+CD25− T cells in the asymptomatic stage of FIV disease, as has
been shown in HIV chronic progressors not on HAART therapy, though
we did not determine their capacity to produce virus or infect other
cells (Chase et al., 2008). In our model, because Treg cells do not
appear to be a viral reservoir anymore than conventional CD4+ T cells
during the chronic phase, it is unlikely that Treg cell depletion would
be sufﬁcient therapy itself to reduce viral burden in the individual.
These studies demonstrate that in vivo depletion of CD4+CD25hi
Treg cells unmasks antiviral T cell responses in chronically FIV-
infected cats without affecting viral load positively or negatively.
Short-term removal of Treg cells in HIV-infected patients who are
controlling viral load could be beneﬁcial to the patients' disease
prognosis. Further investigation into a Treg cell depletion strategy for
therapeutic vaccination is justiﬁed due to the indication that transient
Treg cell depletion can create a window of opportunity to induce
novel immune responses during lentiviral infection.
Materials and methods
Animals, viral inoculum, and monoclonal antibody administration
A total of 26 female speciﬁc-pathogen-free (SPF) cats were
purchased from Liberty Labs (Liberty, NY). Cats were housed and
cared for in accordance with Association for the Assessment of
Laboratory Animal Care standards and Institutional Animal Care and
Use Committee guidelines. Cats were infected with the pathogenic
molecular clone FIV-NCSU1 by intravaginal and intravenous routes
between 24 and 43 weeks of age (Tompkins et al., 1991). Mouse anti-
feline CD25 hybridoma (9F23) (Ohno et al., 1992), a gift from M.
Honda at the National Institutes of Health in Tokyo, Japan, and mouse
anti-yellow fever antigen (YFA) hybridoma (CRL-1689; ATCC, Man-
assas, VA) were expanded, puriﬁed, and certiﬁed endotoxin- and
mycoplasma-free by Leinco, Inc. (St. Louis, MO). Two groups of cats
received one injection of 9 mg/kg anti-feline CD25 mAb intraper-
itoneally (i.p.) at 10 to 14 months post-infection (Smithberg et al.,
2008). Two additional groups were treated with 9 mg/kg anti-YFA
mAb i.p. as a mouse IgG2a κ light chain isotype control mAb. Another
group received 3 ml/kg 0.9% sodium chloride (Hospira, Lake Forest,
IL) i.p. as a vehicle control.
Sample collection and processing
Whole blood was collected into Vacutainer tubes (BD, Franklin
Lakes, NJ) containing ACD on days 0, 10, 21, 29, 42, and 60 or days 0,
10, and 23 after treatment. PBMCs were isolated by centrifugation of
blood over Histopaque (Sigma, St. Louis, MO) and serum was
processed as previously described (Burkhard et al., 2001; Stevens
170 S.R. Mikkelsen et al. / Virology 403 (2010) 163–172et al., 2004). Blood for plasma isolation, complete blood counts, and
leukocyte differentials was collected in Vacutainer tubes containing
EDTA. Plasma was isolated by centrifugation (800×g for 10 min) and
aliquots were frozen at −80 °C. Popliteal lymph node (LN) biopsies
were performed on anesthetized cats either 28 days before treatment
or 29 days post-treatment or on day 0. At day 23 or 60 post-treatment,
mesenteric, prescapular, retropharyngeal, and medial iliac LNs in
addition to spleen and distal small intestine were harvested and
processed as described previously (Dean and Pedersen, 1998; Howard
et al., 2005). In some cases, popliteal and prescapular LNs were sorted
for CD4+CD25+, CD4+CD25−, CD8+, and CD21+ lymphocytes on a
MoFlo cell sorter (Dako, Fort Collins, CO). Isolated cell populations
were at least 95% pure. Cells were used immediately in ex vivo assays
or cell aliquots were frozen at −80 °C for subsequent RNA and DNA
isolation.
Phenotypic analysis
At least 1×106 cells were labeled with the following antibodies for
ﬂow cytometric analysis. Anti-CD3 (NZM1) (Nishimura et al., 2004),
anti-CD4 (30A) (Tompkins et al., 1990), and anti-CD8α (3.357)
(Tompkins et al., 1990) were used unconjugated to ﬂuorochromes.
CD4-PE (3-4F4) and CD5-biotin (F43) were purchased from Southern
Biotech (Birmingham, AL). CD14-PE (Tuk4; Dako) and CD21-FITC
(CA2-1D6; Serotec, Raleigh, NC) were purchased. Goat anti-mouse
IgG-Cy5 (Jackson Immunoresearch, West Grove, PA) or streptavidin–
PerCP (BD Biosciences, San Diego, CA) was used as secondary
ﬂuorochromes. Anti-CD8α (3.357) was conjugated to PerCP using a
kit from Prozyme (San Leandro, CA). Intracellular FOXP3 staining was
performedwith eBioscience FOXP3 staining buffers and FOXP3–PECy7
(FJK-16s; San Diego, CA) according to the manufacturer's protocol,
with the exception that cells remain in the permeabilization/wash
buffer no longer than 30 min. For intracellular cytokine staining, cells
were incubated with 1× monensin (Biolegend, San Diego, CA) for 6 h,
labeled for surface markers, ﬁxed with 4% paraformaldehyde,
permeabilized with BD Cytoﬁx/Cytoperm kit Perm/Wash buffer, and
stained with IL-2-PE (MQ1-17H12; BioLegend) and tumor necrosis
factor (TNF)-α-APC (6401.1111; BD). Flow cytometric analysis was
performed using an LSR II ﬂow cytometer and FacsDIVA software (BD).
At least 100,000 gated events were collected per sample.
Because only one anti-feline CD25 mAb (9F23) exists, the same
antibody was used to deplete CD25hi cells in vivo and detect CD25+
cells via ﬂow cytometric analysis. To investigate the possibility that
anti-CD25 mAb administration in vivo would mask labeling with FITC
conjugated anti-CD25 mAb the following study was performed. Ten
FIV-naïve cats were divided into groups of ﬁve each. One group was
treated as described with anti-CD25 mAb and the other with isotype
control mAb. Anti-feline CD25 mAb was conjugated to FITC using
standard protocols. On days 0, 3, 9, 11, 14, 21, 28, and 35, peripheral
blood was collected and PBMCs were labeled in three ways: 1) with
anti-murine IgG2a-FITC (Jackson Immunoresearch), 2) ﬁrstly with
unconjugated anti-CD25 mAb and secondly with anti-murine IgG2a-
FITC, or 3) with anti-CD25mAb conjugated to FITC. Method 1 revealed
the number of cells that were bound by the anti-CD25 mAb in vivo.
Method 2 saturated all CD25+ cells to reveal the total CD25+
population. Method 3 determined whether in vivo-bound antibody
was masking CD25 and preventing additional binding of the antibody
used for ﬂow cytometric analysis. Results are shown in Supplemental
Fig. 1. We found that in vivo anti-CD25 mAb treatment did not
prevent accurate identiﬁcation of CD25+ cell levels via ﬂow
cytometry when method 3 was used.
Viral parameters
Quantitative real-time one-step reverse transcriptase (RT)-PCR
assays were performed on a Bio-Rad MyiQ™ PCR detection system(Hercules, CA). RNA was extracted from plasma using the QIAamp
viral RNAmini kit (Qiagen, Valencia, CA) following themanufacturer's
protocol. Detection of plasma viremia in RNA samples was performed
using FIV Gag speciﬁc primers, FIVNC.491f and FIVNC.617r, and the
FIV-NCSU1-speciﬁc probe FIVNC.555p as described with minor
adjustments (Burkhard et al., 2002). Each RNA sample was incubated
with TaqMan universal PCR master mix without AmpErase® UNG
(Applied Biosystems, Branchburg, NJ), 800 nM forward and reverse
primers, 80 nM TaqMan probe, and 1× Multiscribe™ and RNase
inhibiter mix (Applied Biosystems). Plasma viremia RT-PCR cycling
conditions were as follows: 30 min at 48 °C, 10 min at 95 °C, and
50 cycles of a 15 s step at 95 °C followed by a 1 min step at 57.5 °C.
Fluorescence was recorded at the end of each annealing/extension
step. A 10-fold dilution series of RNA standards provided a detection
range from 101 to 105 RNA molecules per reaction (Burkhard et al.,
2002). Bio-Rad MyiQ™ optical system software v2.0 was used to
generate a standard curve; viral RNA copies/ml plasma was
subsequently calculated.
To detect proviral load in PBMC and tissue samples, quantitative
PCRwas performed on DNA samples extracted with the DNeasy tissue
kit (Qiagen). Each ampliﬁcation reaction included 0.5 µg DNA sample
or standard, TaqMan universal PCR master mix (Applied Biosystems),
491f primer, 617r primer, and 555p probe as described with minor
modiﬁcations (Pedersen et al., 2001). Real-time PCR cycling condi-
tions were as follows: 2 min at 50 °C, 10 min at 95 °C, and 45 cycles of
a 15 s step at 95 °C followed by a 1 min step at 57.5 °C. To normalize
proviral load per 106 cells, 200 nM CCR5 forward primer and 500 nM
CCR5 reverse primer were used in the PCR with 200 nM TaqMan
probe and 50 ng DNA sample. CCR5 primers (forward 5′-ACGTC-
TACCTGCTCAACCTGG-3′, reverse 5′-ACCGTCTTACACATCCCATCCC-3′)
and probe (FAM-5′-TCCGACCTGCTCTTCCTCTTCACCCTCC-3′) were
designed using Beacon Designer. The limit of detection was ≤10
copies of FIV per 1 µg DNA. Standards, controls, and samples were run
in duplicate for real-time PCRs.
Peptides
Peptides (Synpep, Dublin, CA) synthesized from FIV Gag p24 and
FIV Env protein sequences were 15 amino acids (aa) in length. Eight
peptides from FIV p24 and nine peptides from FIV Env determined to
solicit optimum IFN-γ production from FIV-exposed lymphocytes
were pooled as described (Dean et al., 2004). In addition, a peptide
library of the entire FIV p24 sequence of Gag was synthesized by JPT
(Springﬁeld, VA) consisting of 15-aa peptides overlapped by 10 aa.
Peptides were reconstituted in 10% dimethyl sulfoxide (DMSO) and
stored at −80 °C.
Interferon-γ ELISpot
Capture and detection antibodies from the feline IFN-γ detection
module (R&D Systems, Minneapolis, MN) were used with ELISPOT
Immobilon-P 96-well plates (Millipore, Bedford, MA) to quantify IFN-
γ-producing cells after stimulation with FIV p24 or Env optimized
peptide pools as previously described (Stevens et al., 2005). The
protocol was modiﬁed with the use of 2.5 or 5×105 fresh rather than
frozen cells per well.
Anti-mouse serum titers
Serum IgG titers against mouse antibody were determined by
ELISA as previously described (Smithberg et al., 2008).
Statistics
Data were compared by unpaired t-test using GraphPad Prism
version 5.0 (GraphPad Software, San Diego, CA).
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